Clinical Efficacy of Modified Qingjin Quyu Decoction in Treatment of NSCLC with Syndrome of Internal Obstruction of Phlegm-Stasis and Its Influence on Immune Function
Objective To explore the clinical efficacy of modified Qingjin Quyu Decoction in treating non-small cell lung cancer(NSCLC)patients with the syndrome of internal obstruction of phlegm-stasis and its influence on the im-mune function.Methods Ninety-four NSCLC patients admitted to Dazu District People's Hospital of Chongqing from A-pril 2022 to April 2023 were enrolled and divided into a control group and a study group using a simple random number ta-ble,with 47 cases in each group.The control group received conventional chemotherapy,while the study group received the modified Qingjin Quyu Decoction in addition to conventional chemotherapy.The treatment was conducted in cycles of 3 weeks each,with a total of 3 cycles.The clinical efficacy,traditional Chinese medicine(TCM)syndrome scores before and after treatment,tumor markers[cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),and carbohydrate antigen 199(CA199)],Karnofsky Performance Status(KPS),and immune function indicators(CD3+,CD4+,CD4+/CD8+levels)were observed and compared between the two groups.Results The total effective rate after treatment in the study group was 91.49％(43/47),which was higher than 76.60％(36/47)in the control group(P＜0.05).After treatment,the scores for cough,blood in sputum,dyspnea,chest tightness and pain,fatigue,spontaneous sweating,thirst,and dry mouth were significantly reduced in both groups compared to conditions before treatment(P＜0.05),and the scores in the study group were significantly lower than those in the con-trol group(P＜0.05).The levels of serum CYFRA21-1,CA125,CEA,and CA199 were significantly decreased in both groups after treatment compared to those before treatment(P＜0.05),and the levels in the study group were significantly lower than those in the control group(P＜0.05).The KPS scores and CD3+,CD4+,and CD4+/CD8+levels were signifi-cantly increased in both groups after treatment compared to those before treatment(P＜0.05),and the levels in the study group were significantly higher than those in the control group(P＜0.05).Conclusion The modified Qingjin Quyu De-coction on the basis of conventional chemotherapy for NSCLC patients with syndrome of internal obstruction of phlegm-stasis can effectively alleviate clinical symptoms,improve the overall health status,reduce tumor marker levels,enhance disease treatment effectiveness,and improve immune function,thereby facilitating a favorable prognosis.
Qingjin Quyu DecoctionNSCLCPhlegm-Stasis Internal Obstruction SyndromeClinical EfficacyImmune function
万方数据
维普
